Related Experiment Videos
[In vitro decrease of the cytolytic effect of E. histolytica by inhibition of its phosphofructokinase]
E Jiménez Cardoso1, E Cuevas Rosas, J M Jiménez Cardoso
1Laboratorio de Investigación en Parasitología, Hospital Infantil de México Federico Gómez, México D.F.
Revista Latinoamericana De Microbiologia
|October 1, 1992
Summary
Pyrophosphate (PPi) analogues competitively inhibit E. histolytica phosphofructokinase, reducing trophozoite cytolytic activity. Inhibitor III showed the greatest efficacy in reducing parasite lysis and protecting host cells.
Area of Science:
- Biochemistry
- Parasitology
- Enzymology
Context:
- Entamoeba histolytica (E. histolytica) is an anaerobic protozoan parasite responsible for amoebiasis.
- Phosphofructokinase (PFK) is a key enzyme in glycolysis, regulating carbohydrate metabolism.
- Understanding PFK inhibition in E. histolytica could reveal new therapeutic targets.
Purpose:
- To investigate the inhibitory effects of pyrophosphate (PPi) analogues on the PPi-dependent phosphofructokinase of E. histolytica.
- To determine the kinetic parameters of the enzyme and the inhibition constants (Ki) of the PPi analogues.
- To correlate enzyme inhibition with the parasite's cytolytic activity and its ability to damage host cells.
Summary:
- Radioactively labeled PPi analogues were incorporated into E. histolytica trophozoites, with over 90% viability maintained.
- The PPi-dependent phosphofructokinase was isolated, and kinetic parameters were determined. Three PPi analogues competitively inhibited the enzyme.
- Inhibitor III demonstrated the most potent inhibition, requiring the lowest concentration for 50% lysis inhibition and increasing the time for trophozoites to destroy host cells.
Impact:
- Enzymatic inhibition of PPi-dependent phosphofructokinase by PPi analogues modifies trophozoite lytic capacity.
- This inhibition likely alters carbohydrate metabolic pathways within the parasite.
- The findings suggest PPi analogues as potential agents to control E. histolytica infections by targeting its glycolysis.